Functional Service Provider (FSP) CROs
CROs providing specific functional support to pharma sponsors.
Market snapshot
These figures describe Clinical Research Organizations (CRO) (4.9.2), the segment that Functional Service Provider (FSP) CROs sits within — not Functional Service Provider (FSP) CROs on its own.
Within biotech R&D (NAICS 541714, a broad ~$91B research category) and life-sciences services; CROs are not cleanly separated, so the segment is not separately sized here.
Business model & economics
Revenue model
Fee-for-service and full-service trial-management contracts
Key economics
- Recurring revenue
- High
- EBITDA margin
- 15–25%
- Capex intensity
- Low
multi-year program relationships
Characteristics
- Large, consolidated drug-development outsourcing market.
- Trial complexity and R&D outsourcing drive demand.
- Sensitive to the biotech funding cycle.
Geographic concentration
Clinical research organizations concentrate around the life-sciences clusters — Massachusetts and the Maryland biotech corridor — with Delaware and California close behind.
U.S. Census Bureau — 2022 County Business Patterns (establishments by state), NAICS 541714. Concentration shown by location quotient.
M&A deal context
Who’s acquiring
- CRO majors
- Life-sciences-services consolidators
- PE-backed platforms
What’s driving deals
- Consolidation around full-service CRO platforms.
- Biopharma R&D-outsourcing growth.
- Trial-complexity and capability demand.
Find Functional Service Provider (FSP) CROs acquisition targets
Search Acquisera’s index for companies classified under Functional Service Provider (FSP) CROs (4.9.2.2) and build a targeted deal pipeline.
Search companies